BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 17026874)

  • 1. Eosinophilic disorders in children.
    Wagelie-Steffen A; Aceves SS
    Curr Allergy Asthma Rep; 2006 Nov; 6(6):475-82. PubMed ID: 17026874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-interleukin-5 antibody therapy in eosinophilic diseases.
    Simon D; Braathen LR; Simon HU
    Pathobiology; 2005; 72(6):287-92. PubMed ID: 16582580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deposits of eosinophil granule proteins in eosinophilic cholecystitis and eosinophilic colitis associated with hypereosinophilic syndrome.
    Tajima K; Katagiri T
    Dig Dis Sci; 1996 Feb; 41(2):282-8. PubMed ID: 8601370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted Anti-IL-5 Therapies and Future Therapeutics for Hypereosinophilic Syndrome and Rare Eosinophilic Conditions.
    Harish A; Schwartz SA
    Clin Rev Allergy Immunol; 2020 Oct; 59(2):231-247. PubMed ID: 31919743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eosinophils express functional IL-13 in eosinophilic inflammatory diseases.
    Schmid-Grendelmeier P; Altznauer F; Fischer B; Bizer C; Straumann A; Menz G; Blaser K; Wüthrich B; Simon HU
    J Immunol; 2002 Jul; 169(2):1021-7. PubMed ID: 12097410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changing roles of eosinophils in health and disease.
    Furuta GT; Atkins FD; Lee NA; Lee JJ
    Ann Allergy Asthma Immunol; 2014 Jul; 113(1):3-8. PubMed ID: 24795292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of hypereosinophilic syndrome and eosinophilic dermatitis with reslizumab.
    Kuruvilla M
    Ann Allergy Asthma Immunol; 2018 Jun; 120(6):670-671. PubMed ID: 29496465
    [No Abstract]   [Full Text] [Related]  

  • 8. Experimental Modeling of Eosinophil-Associated Diseases.
    Upparahalli Venkateshaiah S; Manohar M; Kandikattu HK; Mishra A
    Methods Mol Biol; 2021; 2241():275-291. PubMed ID: 33486743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Anti-interleukin-5 therapy for eosinophilic diseases].
    Simon D; Braathen LR; Simon HU
    Hautarzt; 2007 Feb; 58(2):122, 124-7. PubMed ID: 17221241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mepolizumab and eosinophil-mediated disease.
    Walsh GM
    Curr Med Chem; 2009; 16(36):4774-8. PubMed ID: 19929788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic strategies for harnessing human eosinophils in allergic inflammation, hypereosinophilic disorders, and cancer.
    Amini-Vaughan ZJ; Martinez-Moczygemba M; Huston DP
    Curr Allergy Asthma Rep; 2012 Oct; 12(5):402-12. PubMed ID: 22875242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of eosinophilic gastrointestinal disorders with other atopic disorders.
    Jyonouchi S; Brown-Whitehorn TA; Spergel JM
    Immunol Allergy Clin North Am; 2009 Feb; 29(1):85-97, x. PubMed ID: 19141344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mepolizumab in eosinophilic disorders.
    Abonia JP; Putnam PE
    Expert Rev Clin Immunol; 2011 Jul; 7(4):411-7. PubMed ID: 21790283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of interleukin-5 for the treatment of eosinophilic diseases.
    Corren J
    Discov Med; 2012 Apr; 13(71):305-12. PubMed ID: 22541618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-interleukin-5 therapy for asthma and hypereosinophilic syndrome.
    Kay AB; Klion AD
    Immunol Allergy Clin North Am; 2004 Nov; 24(4):645-66, vii. PubMed ID: 15474864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Therapies for Eosinophilic Disorders.
    Bochner BS
    Immunol Allergy Clin North Am; 2015 Aug; 35(3):577-98. PubMed ID: 26209901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnoses associated with peripheral blood eosinophilia: A 5-year review.
    Leverone N; Tran S; Barry J; Akuthota P
    Ann Allergy Asthma Immunol; 2021 Nov; 127(5):597-598. PubMed ID: 34391899
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody.
    Smith DA; Minthorn EA; Beerahee M
    Clin Pharmacokinet; 2011 Apr; 50(4):215-27. PubMed ID: 21348536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The spectrum of therapeutic activity of mepolizumab.
    Cavaliere C; Frati F; Ridolo E; Greco A; de Vincentiis M; Masieri S; Makri E; Incorvaia C
    Expert Rev Clin Immunol; 2019 Sep; 15(9):959-967. PubMed ID: 31424304
    [No Abstract]   [Full Text] [Related]  

  • 20. Eosinophilia in mast cell disease.
    Kovalszki A; Weller PF
    Immunol Allergy Clin North Am; 2014 May; 34(2):357-64. PubMed ID: 24745679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.